Roka Bioscience Inc  

(Public, NASDAQ:ROKA)   Watch this stock  
Find more results for ROKA
+0.28 (6.71%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.09 - 4.72
52 week 3.66 - 16.00
Open 4.15
Vol / Avg. 248,966.00/151,089.00
Mkt cap 8.76M
P/E     -
Div/yield     -
EPS -20.14
Shares 1.84M
Beta     -
Inst. own 76%
Mar 2, 2017
Q4 2016 Roka Bioscience Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 7, 2016
Q3 2016 Roka Bioscience Inc Earnings Call
Nov 7, 2016
Q3 2016 Roka Bioscience Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -402.60% -611.53%
Operating margin -381.64% -589.71%
EBITD margin - -479.70%
Return on average assets -48.41% -41.04%
Return on average equity -112.66% -59.04%
Employees 90 -
CDP Score - -


20 Independence Blvd
WARREN, NJ 07059-2731
United States - Map
+1-908-6054700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company's Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Officers and directors

Paul G. Thomas Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Mary Duseau President, Chief Executive Officer, Secretary, Director
Age: 51
Bio & Compensation  - Reuters
Lars Boesgaard Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Nicholas J. Valeriani Director
Age: 59
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Michael P. Doyle Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
David W. J. McGirr Independent Director
Age: 61
Bio & Compensation  - Reuters
Jonathan Todd Silverstein Independent Director
Bio & Compensation  - Reuters